Genprex (NASDAQ: GNPX) Stock Hits Multi-Month High On Heavy Volume
On Monday, the Genprex (NASDAQ: GNPX) stock emerged as one of the biggest movers in the market as it clocked gains of a remarkable 256% amidst heavy interest. Following a key announcement from the company last week, investors piled on to the stock yesterday.
Key Approval
On October 16, Genprex had been in focus after it announced that the SRC (Safety Review Committee) had awarded the company with the approval to move forward to the highest dot group. In the group, the dose would be 0.12 mg/kg, and the initiative would be part of Phase 1 of the Acclaim 3 Trial for its Reqorsa Gene Therapy. The therapy in question is meant for treating those suffering from ES SCLC (extensive stage small cell lung cancer).
The Trial
The trial would be aimed at the evaluation of the gene therapy in addition to maintenance therapy with Tecentriq from Greentech for patients suffering from ES SCLC. The approval came through for Genprex after the company had completed the work with the 0.9 mg/kg dosage group.
In the news release, it was also noted that the approval from the SRC was another demonstration of the REQORSA development program from Genprex. The company expressed its satisfaction with the progress made thus far in the Phase 1 trial and stated that it looked forward to treating the new cohort of patients in the new dosage group.
CEO Comment
Genprex president and CEO Ryan Confer said: “We believe the SRC’s recommendation to advance to the highest dose group of the Phase I portion of the trial is another clinical validation for our REQORSA development program.
“We are proud of the achievements so far in the Phase I portion of the trial, which has demonstrated a favorable safety profile for REQORSA in the first trial to use REQORSA for SCLC patients. We look forward to continuing to treat these patients while we work toward bringing new therapies to lung cancer patients with unmet medical needs.”
Traders Notes
| +/- EMA(20) | 0.4674 (-98.07%) |
| +/- SMA(50) | 2.3497 (-99.62%) |
| +/- SMA(200) | 28.7052 (-99.97%) |
| 5-Day Perf. | -2.17% |
| 1-Month Perf. | -99.61% |
| 3-Month Perf. | -99.74% |
| 6-Month Perf. | -99.96% |
| YTD Perf. | -99.99% |
| 1-Year Perf. | -99.98% |
| RSI(14) | 17.04 |
| ATR(14) | 0.14 |
| ADX(14) | 65.36 |